
Riccardo Spizzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1327515/publications.pdf Version: 2024-02-01



RICCARDO SDIZZO

#	Article	IF	CITATIONS
1	MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 2005, 65, 7065-7070.	0.4	3,719
2	Long non-coding RNAs and cancer: a new frontier of translational research?. Oncogene, 2012, 31, 4577-4587.	2.6	910
3	MicroRNAs — the micro steering wheel of tumour metastases. Nature Reviews Cancer, 2009, 9, 293-302.	12.8	740
4	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	7.7	681
5	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	2.4	526
6	miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts. Cell, 2010, 140, 652-665.	13.5	514
7	Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility. Cancer Research, 2010, 70, 2789-2798.	0.4	365
8	A Genetic Defect in Exportin-5 Traps Precursor MicroRNAs in the Nucleus of Cancer Cells. Cancer Cell, 2010, 18, 303-315.	7.7	299
9	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	3.8	256
10	mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Molecular Cancer, 2007, 6, 54.	7.9	240
11	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-Î \pm in human breast cancer cells. Cell Death and Differentiation, 2010, 17, 246-254.	5.0	231
12	SnapShot: MicroRNAs in Cancer. Cell, 2009, 137, 586-586.e1.	13.5	223
13	Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4394-4399.	3.3	222
14	CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene, 2010, 29, 6390-6401.	2.6	183
15	Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology, 2012, 142, 886-896.e9.	0.6	174
16	<i>CCAT2</i> , a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget, 2013, 4, 1748-1762.	0.8	169
17	miRâ€203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Molecular Oncology, 2014, 8, 83-92.	2.1	156
18	Surface-enhanced Raman spectroscopy of blood plasma and serum using Ag and Au nanoparticles: a systematic study. Analytical and Bioanalytical Chemistry, 2014, 406, 2355-2365.	1.9	152

RICCARDO SPIZZO

#	Article	IF	CITATIONS
19	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery, 2013, 3, 1302-1315.	7.7	140
20	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut, 2016, 65, 977-989.	6.1	111
21	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	3.8	97
22	Surface-enhanced Raman spectroscopy of urine for prostate cancer detection: a preliminary study. Analytical and Bioanalytical Chemistry, 2015, 407, 3271-3275.	1.9	87
23	USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability. Science Advances, 2019, 5, eaav3235.	4.7	79
24	Expression profiling of microRNA using oligo DNA arrays. Methods, 2008, 44, 22-30.	1.9	75
25	SERS analysis of serum for detection of early and locally advanced breast cancer. Analytical and Bioanalytical Chemistry, 2015, 407, 7503-7509.	1.9	70
26	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. PLoS ONE, 2012, 7, e41170.	1.1	59
27	Tcl1 interacts with Atm and enhances NF-Î $^{\circ}$ B activation in hematologic malignancies. Blood, 2012, 119, 180-187.	0.6	48
28	Association between Plasminogen Activator Inhibitor 1 Gene Polymorphisms and Preeclampsia. Gynecologic and Obstetric Investigation, 2003, 56, 17-22.	0.7	45
29	Over-expression of the <i>miR-483-3p</i> overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7, 31361-31371.	0.8	45
30	Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O2ˉ· production in cancer cells. British Journal of Cancer, 2018, 119, 994-1008.	2.9	40
31	RNA Inhibition, MicroRNAs, and New Therapeutic Agents for Cancer Treatment. Clinical Lymphoma and Myeloma, 2009, 9, S313-S318.	1.4	30
32	Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 2512.	1.8	30
33	Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014). Journal of Thoracic Oncology, 2010, 5, 1354-1360.	0.5	24
34	Fhit Delocalizes Annexin A4 from Plasma Membrane to Cytosol and Sensitizes Lung Cancer Cells to Paclitaxel. PLoS ONE, 2013, 8, e78610.	1.1	18
35	Increased Blood Volume and CD34+CD38â^'Progenitor Cell Recovery Using a Novel Umbilical Cord Blood Collection System. Stem Cells, 2000, 18, 245-251.	1.4	17
36	BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress. Cell Death and Disease, 2016, 7, e2374-e2374.	2.7	16

RICCARDO SPIZZO

#	Article	IF	CITATIONS
37	Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma. Melanoma Research, 2013, 23, 96-101.	0.6	13
38	Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis. EBioMedicine, 2019, 46, 79-93.	2.7	13
39	Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress. Current Drug Metabolism, 2016, 17, 542-549.	0.7	13
40	Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer, 2006, 52, 89-92.	0.9	12
41	A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use. Blood Cells, Molecules, and Diseases, 2001, 27, 715-724.	0.6	10
42	Anticancer activity of an adenoviral vector expressing short hairpin RNA against BK virus T-ag. Cancer Gene Therapy, 2007, 14, 297-305.	2.2	7
43	MicroRNAs as new biomarkers in oncology. Expert Opinion on Medical Diagnostics, 2008, 2, 115-127.	1.6	4
44	Flow cytometric characterization of ex vivo expanded umbilical cord blood CD34+ cells. Transplantation Proceedings, 2001, 33, 1764-1765.	0.3	2
45	High-Throughput Profiling in the Hematopoietic System. Methods in Molecular Biology, 2010, 667, 79-91.	0.4	2
46	Multiple Approach to Analyzing the Role of MicroRNAs in Apoptosis. Methods in Molecular Biology, 2009, 559, 219-245.	0.4	2
47	Abstract 2051: DNA (cytosine-5-)-methyltransferases 3A (DNMT3A) is a direct target of miR-194 in breast cancer. Cancer Research, 2010, 70, 2051-2051.	0.4	2
48	Use of miRNA expression profiling to identify novel biomarkers. Personalized Medicine, 2007, 4, 147-155.	0.8	1
49	Abstract 141: miR520d-3p regulates EphA2 and inhibits ovarian cancer growth. , 2011, , .		1
50	Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors Blood, 2009, 114, 855-855.	0.6	0
51	Abstract 1950: Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors. , 2010, , .		0
52	Abstract 4000: Trastuzumab targeting of HER2 upregulates miRNA-194 and downregulates profilin 2 and DNMT3A in HER2 positive breast cancer. , 2011, , .		0